The impact of hypoxia preconditioning on mesenchymal stem cells performance in hypertensive kidney disease

Gurparneet Kaur Sohi,Naba Farooqui,Arjunmohan Mohan,Kamalnath Sankaran Rajagopalan,Li Xing,Xiang Y. Zhu,Kyra Jordan,James D. Krier,Ishran M. Saadiq,Hui Tang,LaTonya J. Hickson,Alfonso Eirin,Lilach O. Lerman,Sandra M. Herrmann
DOI: https://doi.org/10.1186/s13287-024-03778-1
2024-06-12
Stem Cell Research & Therapy
Abstract:Autologous mesenchymal stem cells (MSCs) have emerged as a therapeutic option for many diseases. Hypertensive kidney disease (HKD) might impair MSCs' reparative ability by altering the biomolecular properties, but the characteristics of this impairment are unclear. In our previous pre-clinical studies, we found hypoxic preconditioning (HPC) enhanced angiogenesis and suppressed senescence gene expression. Thus, we hypothesize that HPC would improve human MSCs by enhancing their functionality and angiogenesis, creating an anti-inflammatory and anti-senescence environment.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore the effects of hypoxic preconditioning (HPC) on the characteristics of mesenchymal stem cells (MSCs) from healthy individuals, hypertensive patients and hypertensive kidney disease patients. Specifically, the study aims to evaluate whether HPC can improve the therapeutic potential of these cells by enhancing the functionality of MSCs and promoting angiogenesis, thereby creating an anti - inflammatory and anti - aging environment. By comparing the functional, secretome and transcriptome characteristics of MSCs under different conditions (normoxia and hypoxia), especially focusing on the performance of these cells in hypertensive kidney disease (HKD), the paper hopes to provide new strategies and insights for the treatment of HKD.